Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA
Vroling, H., Oordt-Speets, A.M., Madeddu, G., Babudieri, S., Monarca, R., O'Moore, E., Vonk Noordegraaf-Schouten, M., Wolff, H., Montanari, M., Hedrich, D., Tavoschi, L.
Taking stock: where does Europe stand in the elimination of hepatitis B and C?
In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the authors take a closer look how Europe is doing according to the ten indicators and targets outlined in this plan. In short: Europe still has some way to go if it wants to eliminate viral hepatitis by 2030.
Public health guidance on HIV and STI prevention among men who have sex with men
This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.
HIV and hepatitis B and C in Latvia
At the request of the Ministry of Health in Riga, a team of experts from ECDC and the European Monitoring Centre for Drugs and Drug Addiction paid a technical visit to Latvia on 2–4 September 2014.
3rd Meeting of the Hepatitis B and C Network
On the third meeting of the Hepatitis B and C Network national focal points and experts discussed the enhanced surveillance programme for hepatitis B and C across Europe and explored ways of improving it.
Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections, human immunodeficiency virus, hepatitis B virus and hepatitis C virus that are relevant for the prevention and control of these infections at EU/EEA level.